Does the media prefer XENE or UTHR?

In the previous week, Xenon Pharmaceuticals had 4 more articles in the media than United Therapeutics. MarketBeat recorded 27 mentions for Xenon Pharmaceuticals and 23 mentions for United Therapeutics. United Therapeutics' average media sentiment score of 0.65 beat Xenon Pharmaceuticals' score of -0.31 indicating that United Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Xenon Pharmaceuticals 4 Very Positive mention(s) 1 Positive mention(s) 8 Neutral mention(s) 7 Negative mention(s) 3 Very Negative mention(s) Neutral United Therapeutics 13 Very Positive mention(s) 4 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer GMAB or XENE?

In the previous week, Xenon Pharmaceuticals had 15 more articles in the media than Genmab A/S. MarketBeat recorded 27 mentions for Xenon Pharmaceuticals and 12 mentions for Genmab A/S. Genmab A/S's average media sentiment score of 0.64 beat Xenon Pharmaceuticals' score of -0.31 indicating that Genmab A/S is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Genmab A/S 2 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Xenon Pharmaceuticals 4 Very Positive mention(s) 1 Positive mention(s) 8 Neutral mention(s) 7 Negative mention(s) 3 Very Negative mention(s) Neutral

Does the media favor ASND or XENE?

In the previous week, Xenon Pharmaceuticals had 4 more articles in the media than Ascendis Pharma A/S. MarketBeat recorded 27 mentions for Xenon Pharmaceuticals and 23 mentions for Ascendis Pharma A/S. Ascendis Pharma A/S's average media sentiment score of 0.68 beat Xenon Pharmaceuticals' score of -0.31 indicating that Ascendis Pharma A/S is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Ascendis Pharma A/S 7 Very Positive mention(s) 7 Positive mention(s) 8 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Xenon Pharmaceuticals 4 Very Positive mention(s) 1 Positive mention(s) 8 Neutral mention(s) 7 Negative mention(s) 3 Very Negative mention(s) Neutral

Does the media prefer BBIO or XENE?

In the previous week, Xenon Pharmaceuticals had 19 more articles in the media than BridgeBio Pharma. MarketBeat recorded 27 mentions for Xenon Pharmaceuticals and 8 mentions for BridgeBio Pharma. BridgeBio Pharma's average media sentiment score of 0.87 beat Xenon Pharmaceuticals' score of -0.31 indicating that BridgeBio Pharma is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment BridgeBio Pharma 4 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Xenon Pharmaceuticals 4 Very Positive mention(s) 1 Positive mention(s) 8 Neutral mention(s) 7 Negative mention(s) 3 Very Negative mention(s) Neutral

Is XENE or SMMT more profitable?

Xenon Pharmaceuticals' return on equity of -43.98% beat Summit Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Xenon Pharmaceuticals N/A -43.98% -41.72% Summit Therapeutics N/A -168.94% -141.92%

Does the media favor XENE or SMMT?

In the previous week, Xenon Pharmaceuticals had 20 more articles in the media than Summit Therapeutics. MarketBeat recorded 27 mentions for Xenon Pharmaceuticals and 7 mentions for Summit Therapeutics. Summit Therapeutics' average media sentiment score of 0.20 beat Xenon Pharmaceuticals' score of -0.31 indicating that Summit Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Xenon Pharmaceuticals 4 Very Positive mention(s) 1 Positive mention(s) 8 Neutral mention(s) 7 Negative mention(s) 3 Very Negative mention(s) Neutral Summit Therapeutics 1 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral

Xenon Pharmaceuticals (XENE) Competitors

$39.75 -17.60 (-30.69%)

Closing price 09/18/2026 04:00 PM Eastern

Extended Trading

$39.80 +0.05 (+0.11%)

As of 09/18/2026 07:59 PM Eastern

Compare

XENE vs. UTHR, GMAB, ASND, BBIO, and SMMT

Should you buy Xenon Pharmaceuticals stock or one of its competitors? Xenon Pharmaceuticals's main competitors and comparable companies include United Therapeutics (UTHR), Genmab A/S (GMAB), Ascendis Pharma A/S (ASND), BridgeBio Pharma (BBIO), and Summit Therapeutics (SMMT). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Xenon Pharmaceuticals compare to United Therapeutics?

Xenon Pharmaceuticals (NASDAQ:XENE) and United Therapeutics (NASDAQ:UTHR) are both healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their risk, earnings, analyst recommendations, media sentiment, valuation, profitability, dividends and institutional ownership.

Xenon Pharmaceuticals has a beta of 0.61, suggesting that its stock price is 39% less volatile than the broader market. Comparatively, United Therapeutics has a beta of 0.56, suggesting that its stock price is 44% less volatile than the broader market.

United Therapeutics has higher revenue and earnings than Xenon Pharmaceuticals. Xenon Pharmaceuticals is trading at a lower price-to-earnings ratio than United Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Xenon Pharmaceuticals	$7.50M	512.35	-$345.91M	-$4.74	N/A
United Therapeutics	$3.18B	6.67	$1.33B	$27.95	17.70

United Therapeutics has a net margin of 41.56% compared to Xenon Pharmaceuticals' net margin of 0.00%. United Therapeutics' return on equity of 20.18% beat Xenon Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Xenon Pharmaceuticals	N/A	-43.98%	-41.72%
United Therapeutics	41.56%	20.18%	17.98%

In the previous week, Xenon Pharmaceuticals had 4 more articles in the media than United Therapeutics. MarketBeat recorded 27 mentions for Xenon Pharmaceuticals and 23 mentions for United Therapeutics. United Therapeutics' average media sentiment score of 0.65 beat Xenon Pharmaceuticals' score of -0.31 indicating that United Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Xenon Pharmaceuticals	4 Very Positive mention(s)	1 Positive mention(s)	8 Neutral mention(s)	7 Negative mention(s)	3 Very Negative mention(s)	Neutral
United Therapeutics	13 Very Positive mention(s)	4 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

95.5% of Xenon Pharmaceuticals shares are held by institutional investors. Comparatively, 94.1% of United Therapeutics shares are held by institutional investors. 2.9% of Xenon Pharmaceuticals shares are held by insiders. Comparatively, 8.6% of United Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Xenon Pharmaceuticals currently has a consensus target price of $70.93, indicating a potential upside of 78.45%. United Therapeutics has a consensus target price of $646.00, indicating a potential upside of 30.60%. Given Xenon Pharmaceuticals' stronger consensus rating and higher possible upside, equities research analysts plainly believe Xenon Pharmaceuticals is more favorable than United Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Xenon Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	13 Buy rating(s)	2 Strong Buy rating(s)	2.94
United Therapeutics	0 Sell rating(s)	2 Hold rating(s)	11 Buy rating(s)	0 Strong Buy rating(s)	2.85

Summary

United Therapeutics beats Xenon Pharmaceuticals on 9 of the 17 factors compared between the two stocks.

How does Xenon Pharmaceuticals compare to Genmab A/S?

Genmab A/S (NASDAQ:GMAB) and Xenon Pharmaceuticals (NASDAQ:XENE) are both healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, risk, profitability, institutional ownership, analyst recommendations, dividends, media sentiment and earnings.

Genmab A/S has a beta of 0.84, indicating that its stock price is 16% less volatile than the broader market. Comparatively, Xenon Pharmaceuticals has a beta of 0.61, indicating that its stock price is 39% less volatile than the broader market.

Genmab A/S has higher revenue and earnings than Xenon Pharmaceuticals. Xenon Pharmaceuticals is trading at a lower price-to-earnings ratio than Genmab A/S, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Genmab A/S	$3.72B	5.83	$963M	$1.27	27.35
Xenon Pharmaceuticals	$7.50M	512.35	-$345.91M	-$4.74	N/A

In the previous week, Xenon Pharmaceuticals had 15 more articles in the media than Genmab A/S. MarketBeat recorded 27 mentions for Xenon Pharmaceuticals and 12 mentions for Genmab A/S. Genmab A/S's average media sentiment score of 0.64 beat Xenon Pharmaceuticals' score of -0.31 indicating that Genmab A/S is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Genmab A/S	2 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Xenon Pharmaceuticals	4 Very Positive mention(s)	1 Positive mention(s)	8 Neutral mention(s)	7 Negative mention(s)	3 Very Negative mention(s)	Neutral

Genmab A/S has a net margin of 19.08% compared to Xenon Pharmaceuticals' net margin of 0.00%. Genmab A/S's return on equity of 14.89% beat Xenon Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Genmab A/S	19.08%	14.89%	7.73%
Xenon Pharmaceuticals	N/A	-43.98%	-41.72%

7.1% of Genmab A/S shares are owned by institutional investors. Comparatively, 95.5% of Xenon Pharmaceuticals shares are owned by institutional investors. 1.5% of Genmab A/S shares are owned by insiders. Comparatively, 2.9% of Xenon Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Genmab A/S presently has a consensus price target of $39.50, suggesting a potential upside of 13.70%. Xenon Pharmaceuticals has a consensus price target of $70.93, suggesting a potential upside of 78.45%. Given Xenon Pharmaceuticals' stronger consensus rating and higher probable upside, analysts plainly believe Xenon Pharmaceuticals is more favorable than Genmab A/S.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Genmab A/S	0 Sell rating(s)	3 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.85
Xenon Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	13 Buy rating(s)	2 Strong Buy rating(s)	2.94

Summary

Genmab A/S beats Xenon Pharmaceuticals on 9 of the 17 factors compared between the two stocks.

How does Xenon Pharmaceuticals compare to Ascendis Pharma A/S?

Ascendis Pharma A/S (NASDAQ:ASND) and Xenon Pharmaceuticals (NASDAQ:XENE) are both healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their analyst recommendations, media sentiment, dividends, profitability, valuation, earnings, risk and institutional ownership.

95.5% of Xenon Pharmaceuticals shares are held by institutional investors. 40.0% of Ascendis Pharma A/S shares are held by company insiders. Comparatively, 2.9% of Xenon Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Ascendis Pharma A/S presently has a consensus price target of $310.75, indicating a potential upside of 31.27%. Xenon Pharmaceuticals has a consensus price target of $70.93, indicating a potential upside of 78.45%. Given Xenon Pharmaceuticals' higher possible upside, analysts clearly believe Xenon Pharmaceuticals is more favorable than Ascendis Pharma A/S.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ascendis Pharma A/S	0 Sell rating(s)	1 Hold rating(s)	19 Buy rating(s)	1 Strong Buy rating(s)	3.00
Xenon Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	13 Buy rating(s)	2 Strong Buy rating(s)	2.94

Ascendis Pharma A/S has a beta of 0.35, indicating that its share price is 65% less volatile than the broader market. Comparatively, Xenon Pharmaceuticals has a beta of 0.61, indicating that its share price is 39% less volatile than the broader market.

Ascendis Pharma A/S has higher revenue and earnings than Xenon Pharmaceuticals. Xenon Pharmaceuticals is trading at a lower price-to-earnings ratio than Ascendis Pharma A/S, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ascendis Pharma A/S	$814.57M	18.13	-$258M	$12.89	18.36
Xenon Pharmaceuticals	$7.50M	512.35	-$345.91M	-$4.74	N/A

In the previous week, Xenon Pharmaceuticals had 4 more articles in the media than Ascendis Pharma A/S. MarketBeat recorded 27 mentions for Xenon Pharmaceuticals and 23 mentions for Ascendis Pharma A/S. Ascendis Pharma A/S's average media sentiment score of 0.68 beat Xenon Pharmaceuticals' score of -0.31 indicating that Ascendis Pharma A/S is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Ascendis Pharma A/S	7 Very Positive mention(s)	7 Positive mention(s)	8 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Xenon Pharmaceuticals	4 Very Positive mention(s)	1 Positive mention(s)	8 Neutral mention(s)	7 Negative mention(s)	3 Very Negative mention(s)	Neutral

Ascendis Pharma A/S has a net margin of 70.99% compared to Xenon Pharmaceuticals' net margin of 0.00%. Ascendis Pharma A/S's return on equity of 32.54% beat Xenon Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Ascendis Pharma A/S	70.99%	32.54%	7.71%
Xenon Pharmaceuticals	N/A	-43.98%	-41.72%

Summary

Ascendis Pharma A/S beats Xenon Pharmaceuticals on 11 of the 17 factors compared between the two stocks.

How does Xenon Pharmaceuticals compare to BridgeBio Pharma?

BridgeBio Pharma (NASDAQ:BBIO) and Xenon Pharmaceuticals (NASDAQ:XENE) are both healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their institutional ownership, earnings, risk, dividends, media sentiment, valuation, analyst recommendations and profitability.

Xenon Pharmaceuticals has lower revenue, but higher earnings than BridgeBio Pharma. BridgeBio Pharma is trading at a lower price-to-earnings ratio than Xenon Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BridgeBio Pharma	$502.08M	25.94	-$724.93M	-$3.57	N/A
Xenon Pharmaceuticals	$7.50M	512.35	-$345.91M	-$4.74	N/A

BridgeBio Pharma currently has a consensus target price of $102.61, indicating a potential upside of 54.05%. Xenon Pharmaceuticals has a consensus target price of $70.93, indicating a potential upside of 78.45%. Given Xenon Pharmaceuticals' stronger consensus rating and higher possible upside, analysts clearly believe Xenon Pharmaceuticals is more favorable than BridgeBio Pharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BridgeBio Pharma	1 Sell rating(s)	2 Hold rating(s)	20 Buy rating(s)	0 Strong Buy rating(s)	2.83
Xenon Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	13 Buy rating(s)	2 Strong Buy rating(s)	2.94

In the previous week, Xenon Pharmaceuticals had 19 more articles in the media than BridgeBio Pharma. MarketBeat recorded 27 mentions for Xenon Pharmaceuticals and 8 mentions for BridgeBio Pharma. BridgeBio Pharma's average media sentiment score of 0.87 beat Xenon Pharmaceuticals' score of -0.31 indicating that BridgeBio Pharma is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
BridgeBio Pharma	4 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Xenon Pharmaceuticals	4 Very Positive mention(s)	1 Positive mention(s)	8 Neutral mention(s)	7 Negative mention(s)	3 Very Negative mention(s)	Neutral

BridgeBio Pharma has a beta of 0.97, suggesting that its stock price is 3% less volatile than the broader market. Comparatively, Xenon Pharmaceuticals has a beta of 0.61, suggesting that its stock price is 39% less volatile than the broader market.

Xenon Pharmaceuticals has a net margin of 0.00% compared to BridgeBio Pharma's net margin of -97.03%. BridgeBio Pharma's return on equity of 0.00% beat Xenon Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
BridgeBio Pharma	-97.03%	N/A	-61.19%
Xenon Pharmaceuticals	N/A	-43.98%	-41.72%

99.9% of BridgeBio Pharma shares are held by institutional investors. Comparatively, 95.5% of Xenon Pharmaceuticals shares are held by institutional investors. 14.2% of BridgeBio Pharma shares are held by insiders. Comparatively, 2.9% of Xenon Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Summary

Xenon Pharmaceuticals beats BridgeBio Pharma on 9 of the 17 factors compared between the two stocks.

How does Xenon Pharmaceuticals compare to Summit Therapeutics?

Xenon Pharmaceuticals (NASDAQ:XENE) and Summit Therapeutics (NASDAQ:SMMT) are both healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, dividends, valuation, profitability, risk, earnings, institutional ownership and media sentiment.

95.5% of Xenon Pharmaceuticals shares are owned by institutional investors. Comparatively, 4.6% of Summit Therapeutics shares are owned by institutional investors. 2.9% of Xenon Pharmaceuticals shares are owned by insiders. Comparatively, 83.5% of Summit Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

In the previous week, Xenon Pharmaceuticals had 20 more articles in the media than Summit Therapeutics. MarketBeat recorded 27 mentions for Xenon Pharmaceuticals and 7 mentions for Summit Therapeutics. Summit Therapeutics' average media sentiment score of 0.20 beat Xenon Pharmaceuticals' score of -0.31 indicating that Summit Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Xenon Pharmaceuticals	4 Very Positive mention(s)	1 Positive mention(s)	8 Neutral mention(s)	7 Negative mention(s)	3 Very Negative mention(s)	Neutral
Summit Therapeutics	1 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral

Xenon Pharmaceuticals has higher revenue and earnings than Summit Therapeutics. Summit Therapeutics is trading at a lower price-to-earnings ratio than Xenon Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Xenon Pharmaceuticals	$7.50M	512.35	-$345.91M	-$4.74	N/A
Summit Therapeutics	N/A	N/A	-$1.08B	-$1.12	N/A

Xenon Pharmaceuticals presently has a consensus target price of $70.93, indicating a potential upside of 78.45%. Summit Therapeutics has a consensus target price of $25.91, indicating a potential upside of 45.14%. Given Xenon Pharmaceuticals' stronger consensus rating and higher possible upside, research analysts clearly believe Xenon Pharmaceuticals is more favorable than Summit Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Xenon Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	13 Buy rating(s)	2 Strong Buy rating(s)	2.94
Summit Therapeutics	1 Sell rating(s)	8 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.47

Xenon Pharmaceuticals' return on equity of -43.98% beat Summit Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Xenon Pharmaceuticals	N/A	-43.98%	-41.72%
Summit Therapeutics	N/A	-168.94%	-141.92%

Xenon Pharmaceuticals has a beta of 0.61, suggesting that its share price is 39% less volatile than the broader market. Comparatively, Summit Therapeutics has a beta of -1.24, suggesting that its share price is 224% less volatile than the broader market.

Summary

Xenon Pharmaceuticals beats Summit Therapeutics on 12 of the 15 factors compared between the two stocks.

Get Xenon Pharmaceuticals News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding XENE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

XENE vs. The Competition

Export

Metric	Xenon Pharmaceuticals	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$5.54B	$3.92B	$7.24B	$13.14B
Dividend Yield	N/A	3.65%	2.57%	12.30%
P/E Ratio	-8.39	14.30	275.79	25.40
Price / Sales	512.35	1,415.50	695.58	114.44
Price / Cash	N/A	110.75	77.42	51.66
Price / Book	5.28	15.45	10.46	6.33
Net Income	-$345.91M	-$22.86M	$3.49B	$358.33M
7 Day Performance	-32.23%	-1.21%	0.59%	1.12%
1 Month Performance	-36.22%	-4.42%	-2.01%	-2.67%
1 Year Performance	7.58%	37.81%	18.09%	6.01%

Xenon Pharmaceuticals Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
XENE Xenon Pharmaceuticals	2.6549 of 5 stars	$39.75 -30.7%	$70.93 +78.4%	+5.3%	$5.54B	$7.50M	N/A	370	Trending News Analyst Forecast Gap Down High Trading Volume
UTHR United Therapeutics	4.2811 of 5 stars	$502.70 +1.1%	$646.00 +28.5%	+20.7%	$21.32B	$3.18B	17.99	1,400	Insider Trade
GMAB Genmab A/S	4.2675 of 5 stars	$32.65 +0.6%	$39.50 +21.0%	+23.9%	$20.25B	$4.13B	25.71	3,029	Analyst Revision
ASND Ascendis Pharma A/S	4.7241 of 5 stars	$264.92 +0.5%	$310.80 +17.3%	+18.7%	$16.44B	$814.57M	20.55	1,189	Analyst Downgrade
BBIO BridgeBio Pharma	3.5816 of 5 stars	$72.38 -0.1%	$102.61 +41.8%	+24.9%	$14.16B	$713.07M	N/A	839	Options Volume

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:XENE) was last updated on 9/19/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Xenon Pharmaceuticals (XENE) Competitors

XENE vs. UTHR, GMAB, ASND, BBIO, and SMMT

How does Xenon Pharmaceuticals compare to United Therapeutics?

Summary

How does Xenon Pharmaceuticals compare to Genmab A/S?

Summary

How does Xenon Pharmaceuticals compare to Ascendis Pharma A/S?

Summary

How does Xenon Pharmaceuticals compare to BridgeBio Pharma?

Summary

How does Xenon Pharmaceuticals compare to Summit Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

XENE vs. The Competition

Xenon Pharmaceuticals Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Xenon Pharmaceuticals (XENE) Competitors

XENE vs. UTHR, GMAB, ASND, BBIO, and SMMT

How does Xenon Pharmaceuticals compare to United Therapeutics?

Which has more volatility & risk, XENE or UTHR?

Which has better earnings and valuation, XENE or UTHR?

Is XENE or UTHR more profitable?

Does the media prefer XENE or UTHR?

Do insiders & institutionals have more ownership in XENE or UTHR?

Do analysts recommend XENE or UTHR?

Summary

How does Xenon Pharmaceuticals compare to Genmab A/S?

Which has more risk & volatility, GMAB or XENE?

Which has preferable valuation & earnings, GMAB or XENE?

Does the media prefer GMAB or XENE?

Is GMAB or XENE more profitable?

Do insiders and institutionals hold more shares of GMAB or XENE?

Do analysts recommend GMAB or XENE?

Summary

How does Xenon Pharmaceuticals compare to Ascendis Pharma A/S?

Do insiders and institutionals have more ownership in ASND or XENE?

Do analysts recommend ASND or XENE?

Which has more volatility and risk, ASND or XENE?

Which has higher earnings and valuation, ASND or XENE?

Does the media favor ASND or XENE?

Is ASND or XENE more profitable?

Summary

How does Xenon Pharmaceuticals compare to BridgeBio Pharma?

Which has higher valuation & earnings, BBIO or XENE?

Do analysts rate BBIO or XENE?

Does the media prefer BBIO or XENE?

Which has more volatility and risk, BBIO or XENE?

Is BBIO or XENE more profitable?

Do insiders & institutionals have more ownership in BBIO or XENE?

Summary

How does Xenon Pharmaceuticals compare to Summit Therapeutics?

Do institutionals & insiders have more ownership in XENE or SMMT?

Does the media favor XENE or SMMT?

Which has higher earnings and valuation, XENE or SMMT?

Do analysts prefer XENE or SMMT?

Is XENE or SMMT more profitable?

Which has more volatility and risk, XENE or SMMT?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

XENE vs. The Competition

Xenon Pharmaceuticals Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools